| Gene name: | MCL1 |
| Aging type: | Prevent |
| Aging characteristic: | Others |
| Tissue type: | Tumor tissue |
| Cell name: | HCT116,MCF 10A,MCF-7,MEL526,MEF |
| Experiment: | SA-β-gal activity assay//BrdU assay//Colony formation assay |
| Description: | As control cells induced to senesce have significant increases in the number of nuclear PML bodies compared to untreated cells. However, cells overexpressing Mcl-1 had significant abrogation of senescent changes after treatment, including reduced SA-β-gal+ and no increase in PML foci compared to HCT116 empty vector cells. In contrast, doxorubicintreated control cells formed significantly fewer colonies compared to those overexpressing Mcl-1. In addition, using the BrdU incorporation assay, we observe that the proliferation of cells growing in drug-free media was equivalent regardless of the level of Mcl-1 expression and that doxorubicin treatment of control cells resulted in a marked decrease in BrdU incorporation. |
| Target gene: | P53 |
| Official symbol(s): | P53 |
| R-AG-Target gene: | -- |
| Subcategory: | Unclear |
| Target gene experiment: | SA-β-gal activity assay//Western blot |
| Target gene description: | We noticed that the accumulation of p53 in cells overexpressing Mcl-1 and treated with doxorubicin is the same as in control cells despite a significant difference in SAβ-gal-activity. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...